We are live on
!
Find out more
AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.94B
1-Year Est. Return
374.45%
This Fund
S&P 500
This Quarter
Est. Return
+104.8%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$189M
AUM Growth
–
Cap. Flow
+$150M
Cap. Flow
% of AUM
79.7%
Top 10 Holdings %
Top 10 Hldgs %
55.62%
Holding
62
New
61
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
+$19.9M |
| 2 |
Kura Oncology
KURA
|
+$9.14M |
| 3 |
BridgeBio Pharma
BBIO
|
+$7.48M |
| 4 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
+$6.35M |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$5.28M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.89% |
| 2 | Financials | 1.08% |
| 3 | Consumer Staples | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Aldeyra Therapeutics
ALDX
$103M
| $686K | 0.36% |
+100,000
| New | +$702K |
|
52
C4 Therapeutics
CCCC
$396M
| $663K | 0.35% |
+20,000
| New | +$580K |
|
|
VINCW
53
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
| $627K | 0.33% |
+190,000
| New | +$632K |
|
|
LYRA
54
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $570K | 0.3% |
+1,000
| New | +$563K |
|
55
Outset Medical
OM
$75.3M
| $568K | 0.3% |
+667
| New | +$514K |
|
56
Madrigal Pharmaceuticals
MDGL
$12.4B
| $556K | 0.29% |
+5,000
| New | +$611K |
|
57
CRISPR Therapeutics
CRSP
$4.63B
| $536K | 0.28% |
+3,500
| New | +$414K |
|
|
CEREW
58
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
| $409K | 0.22% |
+72,466
| New | +$292K |
|
|
VXRT
59
PUT
DELISTED
Vaxart
VXRT
| $143K | 0.08% |
+25,000
| New | +$159K |
|
|
SKINW
60
DELISTED
The Beauty Health Company Warrant expiring 5/4/2026
SKINW
| $88K | 0.05% |
+33,333
| New | +$74.4K |
|
|
ZYNE
61
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $44K | 0.02% |
+13,285
| New | +$50.4K |
|
Similar funds
FM
1SB
HCL
OCM
MWA
AF
NFG
HC
Affinity Asset Advisors's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Affinity Asset Advisors, which disclosed 62 positions worth $189M. Its ten largest holdings account for 56% of the portfolio.
Its largest position is Eidos Therapeutics, Inc. Common Stock: 225,000 shares worth $29.6M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, followed by Financials and Consumer Staples.
- Affinity Asset Advisors's largest Q4 2020 buy was Eidos Therapeutics, Inc. Common Stock: 225,000 shares worth $29.6M.
- Affinity Asset Advisors's ten largest holdings make up 56% of its $189M portfolio in Q4 2020.
- Affinity Asset Advisors disclosed 62 positions in Q4 2020, its first 13F filing on record.
Based on Affinity Asset Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.